Probing cytosolic nucleic acid sensing pathways in cancer
探索癌症中的胞质核酸传感途径
基本信息
- 批准号:10321271
- 负责人:
- 金额:$ 70.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:Antitumor ResponseBackBiological AssayBreast Cancer ModelBypassCXCL10 geneCell Differentiation processCell ShapeCellsChromosomal InstabilityChronicClustered Regularly Interspaced Short Palindromic RepeatsCytoplasmCytosolDNADataDependenceDevelopmentDouble-Stranded RNAEmbryonic DevelopmentEpithelialGene SilencingGene TargetingGenesGenetic TranscriptionGenetically Engineered MouseGenomic InstabilityImmuneImmune responseImmune systemImmunotherapyIn VitroInflammationInflammation MediatorsInflammatoryInflammatory ResponseInterferon Type IInterferonsKnock-outLinkLogicMalignant NeoplasmsMalignant neoplasm of lungMammalian CellMapsMediatingMediator of activation proteinMedicineMusMutagenesisNatureNeoplasm MetastasisNormal CellNucleic AcidsOutputPathway interactionsPhenotypePredispositionProcessProductionReporterResistanceRoleSTING agonistsSTING1 geneSignal TransductionSourceStimulator of Interferon GenesStimulusSystemTestingTherapeuticThinkingTransplantationTumor ImmunityViralWorkanti-tumor immune responseautoinflammatorycancer cellcancer cell differentiationcombinatorialcytokineds-DNAearly phase clinical trialexperimental studygenetic manipulationimmune activationimmune checkpoint blockadeimmune resistancein vivoinnate immune pathwaysinterestmanmouse modelneoplastic cellnovelpancreatic cancer modelprogenitorprogramsreceptorresistance mechanismresponsesensorsingle cell sequencingstemstem cellssynergismtherapeutically effectivetherapy developmenttissue regenerationtranscription factortumortumor heterogeneityvectorwound healing
项目摘要
ABSTRACT
The ability of mammalian cells to elicit inflammation is central to many processes including embryogenesis,
wound healing, tissue regeneration, and cancer metastasis. A major source of inflammatory signaling is the
aberrant presence of double-stranded (ds) nucleic acids in the cytoplasm. Mammalian cells have evolved high-
ly conserved mechanisms to detect cytosolic nucleic acids as an anti-viral defense. In normal cells, cGAS (cy-
clic GMP-AMP synthase) and its downstream signaling effector STING (stimulator of interferon genes) have
been proposed as essential mediators of type I interferon (IFN) signaling and downstream immune activation.
We have shown however, that in cancer cells with chromosomal instability (CIN), there is no evidence of type I
IFN signaling despite the presence of cytosolic DNA and constitutive activation of cGAS and STING. Instead,
cancer cells rewire their signaling downstream of STING to selectively suppress IFN signaling and enable oth-
er pro-metastatic pathways such as NF-κB. Three important pieces of evidence bring into question the essen-
tiality of the cGAS-STING pathway in promoting anti-tumor immunity and suggest heretofore unappreciated
redundancies and context dependence of nucleic acid sensing in cancer: 1) chromosomally unstable cancer
cells retain IFN-responsiveness to cytosolic dsRNA. 2) Cancer cells with CIN can still elicit a robust, anti-tumor
immune response to cytosolic dsDNA, in a manner independent of cGAS-STING and type I IFN. 3) Expression
of nucleic acid sensors and downstream inflammatory pathways is highly variable across tumor subpopulations
and metastatic cell states – in which a continuum of stem-like to more committed epithelial progenitors is ob-
served. Together, these findings challenge the current view that cGAS-STING signaling is the universal media-
tor of inflammation in response to cytosolic dsDNA. Herein, we aim to understand functional redundancies and
interactions across cytosolic nucleic acid sensing pathways and how their transcriptional outputs vary with tu-
mor cell differentiation status. We will systematically interrogate key nucleic acid sensors and their downstream
effectors in three syngeneic mouse models characterized by increased metastatic potential and high levels of
CIN. We will experimentally manipulate CIN rates to identify cytosolic nucleic acid-dependent, but cGAS-
STING-independent mechanisms of immune activation (Aim 1). We will then couple high-throughput single-cell
sequencing with combinatorial CRISPR-mediated gene inactivation of key cytosolic nucleic acid sensors and
effectors in metastasis-initiating stem cells distinguished by SOX2 expression, versus their more differentiated
counterparts, to map the cell state-specific regulatory logic of this pathway (Aim 2). Unraveling the context-
dependence of this extremely important and versatile signaling cascade has the potential to transform our
thinking about chronic inflammation in cancer and to reveal therapeutic vulnerabilities in chromosomally unsta-
ble cancer cells that are otherwise resistant to cGAS-STING signaling.
抽象的
哺乳动物细胞引发炎症的能力是许多过程的核心,包括胚胎发生、
伤口愈合、组织再生和癌症转移是炎症信号的主要来源。
哺乳动物细胞的细胞质中异常存在双链(ds)核酸。
在正常细胞中,cGAS(cy-)是检测胞质核酸作为抗病毒防御的保守机制。
clic GMP-AMP 合酶)及其下游信号效应器 STING(干扰素基因刺激器)
已被提议作为 I 型干扰素 (IFN) 信号传导和下游免疫激活的重要介质。
然而,我们已经证明,在具有染色体不稳定 (CIN) 的癌细胞中,没有证据表明 I 型
尽管存在胞质 DNA 以及 cGAS 和 STING 的组成型激活,但 IFN 信号传导相反。
癌细胞重新连接 STING 下游的信号传导,以选择性抑制 IFN 信号传导并启用其他功能
呃促转移途径,例如 NF-κB,三个重要的证据对本质提出了质疑。
cGAS-STING 通路在促进抗肿瘤免疫方面的重要性,并表明迄今为止尚未得到重视
癌症中核酸传感的冗余和背景依赖性:1)染色体不稳定的癌症
细胞保留对胞浆 dsRNA 的 IFN 反应性 2) 具有 CIN 的癌细胞仍然可以引发强大的抗肿瘤作用。
对胞质 dsDNA 的免疫反应,其方式独立于 cGAS-STING 和 I 型 IFN 3) 表达。
核酸传感器和下游炎症途径的变化在肿瘤亚群中存在很大差异
和转移细胞状态——其中干细胞样到更定向的上皮祖细胞的连续体是观察到的
这些发现共同挑战了当前的观点,即 cGAS-STING 信号传导是通用媒体。
在此,我们的目标是了解功能冗余和炎症反应。
跨胞质核酸传感途径的相互作用以及它们的转录输出如何随tu-变化
我们将系统地研究关键的核酸传感器及其下游。
三种同基因小鼠模型中的效应子,其特征是转移潜力增加和高水平
我们将通过实验操纵 CIN 率来识别胞质酸依赖性但 cGAS-
独立于 STING 的免疫激活机制(目标 1)然后我们将耦合高通量单细胞。
通过组合 CRISPR 介导的关键胞质核酸传感器基因失活进行测序
转移起始干细胞中的效应子通过 SOX2 表达来区分,与其分化程度更高的干细胞相比
臂,绘制该通路的细胞状态特异性调控逻辑(目标 2)。
这种极其重要且多功能的信号级联的依赖性有可能改变我们的
思考癌症中的慢性炎症并揭示染色体不稳定的治疗脆弱性
ble 癌细胞,否则对 cGAS-STING 信号有抵抗力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samuel F Bakhoum其他文献
Samuel F Bakhoum的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Samuel F Bakhoum', 18)}}的其他基金
Dissecting the impact of tumor-intrinsic chromosomal instability on the cancer ecosystem
剖析肿瘤内在染色体不稳定性对癌症生态系统的影响
- 批准号:
10651060 - 财政年份:2023
- 资助金额:
$ 70.46万 - 项目类别:
Probing cytosolic nucleic acid sensing pathways in cancer
探索癌症中的胞质核酸传感途径
- 批准号:
10540410 - 财政年份:2021
- 资助金额:
$ 70.46万 - 项目类别:
Targeting innate immune pathways in breast cancers with chromosomal instability
针对染色体不稳定乳腺癌的先天免疫途径
- 批准号:
10478013 - 财政年份:2020
- 资助金额:
$ 70.46万 - 项目类别:
Targeting innate immune pathways in breast cancers with chromosomal instability
针对染色体不稳定乳腺癌的先天免疫途径
- 批准号:
10237882 - 财政年份:2020
- 资助金额:
$ 70.46万 - 项目类别:
Targeting innate immune pathways in breast cancers with chromosomal instability
针对染色体不稳定乳腺癌的先天免疫途径
- 批准号:
10704103 - 财政年份:2020
- 资助金额:
$ 70.46万 - 项目类别:
The role of chromosomal instability in tumor evolution
染色体不稳定性在肿瘤进化中的作用
- 批准号:
10249224 - 财政年份:2018
- 资助金额:
$ 70.46万 - 项目类别:
相似国自然基金
基于裂隙黄土斜坡模型试验的渐进后退式滑坡成灾机理研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
嵌入后退式分离的复杂流动干扰与分离动力学研究
- 批准号:U21B2054
- 批准年份:2021
- 资助金额:260 万元
- 项目类别:联合基金项目
滑模与适定运动统一的稳定条件及基于值函数的受约束切换系统控制研究
- 批准号:61773006
- 批准年份:2017
- 资助金额:51.0 万元
- 项目类别:面上项目
干热河谷冲沟沟头后退的水力、重力协同作用机制
- 批准号:41571277
- 批准年份:2015
- 资助金额:74.0 万元
- 项目类别:面上项目
农户异质性、碳汇生产激励与后退耕时代生态补偿机制研究——以黄土高原退耕区为例
- 批准号:71403214
- 批准年份:2014
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
首创肌球蛋白 10 抑制剂作为胶质母细胞瘤新靶标的药物发现
- 批准号:
10595848 - 财政年份:2021
- 资助金额:
$ 70.46万 - 项目类别:
Probing cytosolic nucleic acid sensing pathways in cancer
探索癌症中的胞质核酸传感途径
- 批准号:
10540410 - 财政年份:2021
- 资助金额:
$ 70.46万 - 项目类别:
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
首创肌球蛋白 10 抑制剂作为胶质母细胞瘤新靶标的药物发现
- 批准号:
10355649 - 财政年份:2021
- 资助金额:
$ 70.46万 - 项目类别:
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
同源重组卵巢癌的表观遗传药物治疗方案
- 批准号:
10117210 - 财政年份:2020
- 资助金额:
$ 70.46万 - 项目类别:
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
同源重组卵巢癌的表观遗传药物治疗方案
- 批准号:
10578788 - 财政年份:2020
- 资助金额:
$ 70.46万 - 项目类别: